BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive dis…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $0.07 | $0.06 | $0.06 |
| Estimado | $0.09 | $0.07 | $0.05 | $0.03 |
| Sorpresa | — | +0.0% | +20.0% | +100.0% |
| Métrica | BWAY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 74.6% | 57.4% | +17.2% |
| Operating Margin | 3.4% | -34.4% | +37.8% |
| Net Margin | 7.1% | -32.5% | +39.6% |
| FCF Margin | — | -12.6% | — |
| ROE | 4.7% | -39.2% | +43.9% |
| ROA | 3.1% | -30.9% | +34.0% |
| Current Ratio | 5.19 | 2.73 | +2.46 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 3.1% | — |
| ✓Flujo de caja operativo positivo | $10M | $1M |
| ✓Rentabilidad sobre activos al alza | 3.1% | -6.7% |
| ✓Caja operativa/activos supera al ROA | 10.9% | ROA 3.1% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 5.19 | 5.68 |
| ✗Sin aumentar el nº de acciones | 34M | 33M |
| ✓Margen bruto al alza | 74.6% | 73.9% |
| ✗Rotación de activos al alza | 0.43 | 0.50 |
| Calidad del negocio | FY24 |
|---|---|
| ✗ROCE > 10 % | 1.8% |
| ✓Ventas > 5 %/año (3 años) | 11.4% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 17.5% |
Brainsway Ltd. cotiza a 11.44 USD y tiene una capitalización bursátil de $460M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud